VISEN Pharmaceuticals (HKG:2561)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
32.56
+1.06 (3.37%)
Mar 10, 2026, 3:59 PM HKT
Market Cap 3.31B
Revenue (ttm) 921.55K
Net Income (ttm) -237.56M
Shares Out 105.02M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,700
Average Volume 8,615
Open 31.50
Previous Close 31.50
Day's Range 31.50 - 32.98
52-Week Range 29.06 - 69.15
Beta n/a
RSI 46.68
Earnings Date Mar 12, 2026

About VISEN Pharmaceuticals

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company’s lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia; and Palopegteriparatide, a once-daily parathyroid hormone replacement therapy f... [Read more]

Sector Healthcare
Founded 2018
Employees 54
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2561
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.